注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Coherus BioSciences Inc是一家商业化的生物制药公司。该公司专注于治疗癌症的免疫疗法的研究、开发和商业化。该公司的业务是开发人类医药产品并将其商业化。该公司的产品线包括三种候选产品,托瑞帕利单抗是一种抗PD-1抗体,正在与Junshi Biosciences Co., Ltd.合作开发,CIMERLI是生物仿绿脓杆菌候选产品,在美国和加拿大获得了Bioeq的商业许可,以及Innovent Biologics (Suzhou) Co., Ltd在美国获得商业许可的贝伐单抗(阿瓦斯汀)生物仿制药。该公司还在开发临床前和转化科学、生物信息学、分析表征、过程科学工程以及临床监管开发和商业化的内部免疫肿瘤学管道。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Mary T. Szela | 58 | 2014 | Independent Director |
Dennis M. Lanfear | 66 | 2010 | Chairman, President & CEO |
Michael Ryan | - | 2023 | Director |
James M. Daly | 61 | 2016 | Member of Strategic Advisory Board |
Jill O’Donnell-Tormey | 67 | 2022 | Independent Director |
Michael Lee Ryan | - | 2023 | Director |
Daniel G. Welch | 65 | 2023 | Member of Strategic Advisory Board |
Angus C. Russell | 67 | 2023 | Member of Strategic Advisory Board |
Taofeek K. Owonikoko | - | 2022 | Member of Scientific Advisory Board |
J. Leighton Read | 72 | 2023 | Member of Strategic Advisory Board |
Christopher A. Hunter | - | 2023 | Member of Scientific Advisory Board |
John Stagg | - | 2023 | Member of Scientific Advisory Board |
Alexander Rudensky | - | - | Member of Scientific Advisory Board |
John Wherry | - | - | Member of Scientific Advisory Board |
Georgia L. Erbez | 57 | 2024 | Director |
Ali J. Satvat | 47 | 2014 | Independent Director |
Thomas Graeber | - | 2021 | Member of Scientific Advisory Board |
Mats L. Wahlstrom | 70 | 2012 | Lead Independent Director |
Mark D. Stolper | 53 | 2021 | Independent Director |
Charles W. Newton | 53 | 2022 | Independent Director |
Carl F. Ware | - | 2021 | Member of Scientific Advisory Board |
Kimberly J. Tzoumakas | 56 | 2020 | Independent Director |
Lee N. Newcomer | 72 | 2022 | Independent Director |
Theresa M. Lavallee | 58 | 2022 | Chief Development Officer & Chairman of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核